Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
(18E)-29-methylidene-2,3-oxidosqualene
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
(18Z)-29-methylidene-2,3-oxidosqualene
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
-
IC50: 31.8 nM
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
-
IC50: 15.7 nM
(4aalpha,5alpha,6alpha,8abeta)-Decahydro-5,8a-dimethyl-2-(1,5,9-trimethyldecyl)-6-isoquinolinol
-
and simplified analogues
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
(5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
1,2-dilinoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, no inhibition at 0.25 microM
1,2-dimyristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
72% inhibition at 0.5 microM, 51% at 0.25 microM
1,2-dioleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
57% inhibition at 0.5 microM, 42% at 0.25 microM
1,2-dipalmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
24% inhibition at 0.5 microM, 4% at 0.25 microM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
1-(2-oxazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
87% inhibition at 0.001 mM
1-(2-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
8% inhibition at 0.001 mM
1-(2-thiazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM
1-(4-iodophenylsulfonyl)-4-(1-(4-pyridyl)piperidon-4-ylcarbonyl)piperazine
-
IC50: 82 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
1-linolenoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, 5% inhibition at 0.25 microM
1-linoleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 18% at 0.25 microM
1-linoleoyl-2-myristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
38% inhibition at 0.5 microM, 22% at 0.25 microM
1-linoleoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
31% inhibition at 0.5 microM, 8% at 0.25 microM
1-linoleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
27% inhibition at 0.5 microM, 3% at 0.25 microM
1-myristoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 35% at 0.25 microM
1-oleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
29% inhibition at 0.5 microM, 7% at 0.25 microM
1-oleoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
40% inhibition at 0.5 microM, 9% at 0.25 microM
1-oleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
46% inhibition at 0.5 microM, 24% at 0.25 microM
1-palmitoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
20% inhibition at 0.5 microM, no inhibition at 0.25 microM
1-palmitoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
21% inhibition at 0.5 microM, 4% at 0.25 microM
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
-
-
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
10,15-desdimethyl-2,3-oxidosqualene
-
-
10-desmethyl-2,3-oxidosqualene
-
-
18,19-dihydro-29-methylidene-2,3-oxidosqualene
-
IC50: 0.1 mM
18-heptanor-2,3-oxidosqualene
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
19-Azasqualene-2,3-epoxide
2,2-dimethyl-3-[(3E,7E,11E,15E)-3,7,12,16,20-pentamethylhenicosa-3,7,11,15,19-pentaen-1-yl]aziridine
-
-
2,3,18,19-Dioxidosqualene stereoisomers
-
-
2,3-Epoxy-10-aza-10,11-dehydrosqualene
2-Aza-2,3-dihydrosqualene
2-aza-2,3-dihydrosqualene alcohol
-
-
2-Aza-2,3-dihydrosqualene N-oxide
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
22,23-Epoxy-2-aza-2,3-dihydrosqualene
-
slight
22,23-epoxy-2-aza-2,3-dihydrosqualene-N-oxide
-
0.01 mM, 14% inhibition
27,28-bisnoroxidosqualene
-
irreversible inhibition
29-methylidene-2,3-oxidohexanorsqualene
-
-
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
3-carboxy-4-nitrophenyldithio-1,1',2-tris-nor-squalene
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
3-[Methyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-amino]-propan-1-ol
-
0.01 mM, 2% inhibition
3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride
-
U18666A
4,4,10beta-trimethyl-trans-decal-3beta-ol
-
specific inhibitor
4-(4-bromobenzoyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
96% inhibition at 0.001 mM
4-(4-bromophenylmethyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
complete inhibition at 0.001 mM
4-chloro-N-(4-{4-[(dimethylamino)methyl]phenyl}cyclohexyl)-N-methylbenzamide
-
BIBX 79
6-desmethyl-2,3-oxidosqualene
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
7-(morpholinyl-N-hexyloxy)chromen-2-one
7-(morpholinyl-N-octanyloxy)chromen-2-one
7-(piperidinyl-N-hexyloxy)chromen-2-one
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
-
IC50: 4.1 nM
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 7.9 nM
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 3.5 nM
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
-
IC50: 19.6 nM
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
-
IC50: 5.6 nM
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
-
IC50: 2.9 nM
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
-
IC50: 11.4 nM
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
-
IC50: 12.3 nM
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
-
IC50: 7.8 nM
azasqualene alcohol
-
0.01 mM, 13% inhibition
azasqualene alcohol N-oxide
dehydrocostus lactone
-
isolated from Laurus nobilis extract, 22% inhibition at 0.25 mM, 63% inhibition at 0.5 mM
diethyl dicarbonate
-
maximal inactivation at neutral pH, ´reactivation by hydroxylamine
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
dodecyl-maleimide
-
mutant C457D shows 41.6% inhibition at 1 mM, 10.0% at 0.2 mM, and 7.2% at 0.025 mM, mutant C457D/E526A shows 9.0% inhibition at 0.2 mM and 0.0% at 0.025 mM, mutant C457D/A525C shows 86.0% inhibition at 1 mM, 30.5% at 0.2 mM, and 1.0% at 0.025 mM, mutant C457D/E526C shows 89.6% inhibition at 0.2 mM, 74.7% at 0.025 mM, and 45.1% at 0.01 mM
eremanthine
-
isolated from Laurus nobilis extract, 12% inhibition at 0.25 mM, 70% inhibition at 0.5 mM
ethanol extract from Angelica keiskei leaves
-
11% inhibition at 0.3 mg/ml
-
ethanol extract from Basella rubra leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium flowers
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium leaves
-
7% inhibition at 0.3 mg/ml
-
ethanol extract from Colocasia esculenta rhizomes
-
55% inhibition at 0.3 mg/ml
-
ethanol extract from Cryptotaenia japonica leaves
-
10% inhibition at 0.3 mg/ml
-
ethanol extract from Glycine max immature seeds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Oenanthe stolonifera leaves
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Perilla frutescens leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Petasites japonicus buds
-
6% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale buds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale rhizomes
-
6% inhibition at 0.3 mg/ml
-
N,N-Diethylazasqualene
-
non-competitive
N,N-Diethylazasqualene N-oxide
-
competitive
N,N-dimethyl-N-(4-methylenebenzophenonyl)amine
-
IC50: 0.005 mM
N,N-Dimethylformamide
-
-
N-(1-Oxododecyl)-4alpha,10-dimethyl-8-aza-trans-decal-3beta-ol
-
potent, competitive
N-(2-methylenebenzophenonyl)pyridinium
-
IC50: 0.059 mM
N-(3-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.016 mM
N-(4-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.00079 mM
N-(Ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline
-
slight
N-[(1,5,9)-Trimethyl-decyl]-4alpha,10-dimethyl-8-aza-decal-3beta-ol
-
strong
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
inactive at 200 nM
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
-
-
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
N-[3-(1,1'-biphenyl-4-yloxy)propyl]-N,N-dimethylamine
-
IC50: 2500 nM
NaCl
-
at high concentrations
Sulfur-substituted squalene oxide analogues
-
trans-N-(4-(5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl)-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide fumarate
-
RO0714565
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
[19-(3,3-Dimethyl-oxiranyl)-4,8,13,17-tetramethyl-nonadeca-4,8,12,16-tetraenyl]-dimethyl-amine
-
0.01 mM, 8% inhibition
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-methanone fumarate
-
Ro 48-8071
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
-
IC50: 6.3 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
-
IC50: 4.6 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
-
IC50: 4.1 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
-
IC50: 6.2 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
-
IC50: 5.4 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
-
IC50: 1.9 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
-
IC50: 6.7 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
-
IC50: 22.5 nM
[5-(4-(4-chloro-benzoyl)-3-fluoro-phenoxy)-pentyl]-methyl-propyl-ammonium fumarate
-
IC50: 49 nM
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
-
IC50: 8.7 nM
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
-
IC50: 35.3 nM
{4-[4-(4,5-Dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone
-
IC50: 90 nM, complete inhibition at 0.001 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0015 mM
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0004 mM
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0015 mM, irreversible; potent, irreversible
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0035 mM, irreversible; potent, irreversible
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0015 mM
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0035 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.03 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.015 mM; potent, irreversible
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.02 mM; potent, irreversible
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.001 mM
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0004 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.06 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.05 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.1 mM
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0015 mM
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.012 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.04 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.0075 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.0025 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.001 mM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 143 nM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 326 nM
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.0015 mM
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.00005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.001 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.018 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.032 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.003 mM, at a protein concentration of 3 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.0048 mM, at a protein concentration of 5 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 2 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 1 mg/ml
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.005 mM
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.004 mM
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 3 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.02 mM, at a protein concentration of 5 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 2 mg/ml
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
-
poor
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.012 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0022 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.001 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0004 mM
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 124 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 112 nM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
76% inhibition at 0.001 mM, IC50: 398 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 37 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM, IC50: 116 nM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.07 mM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.015 mM
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.022 mM, protein concentration of 3 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0075 mM, protein concentration of 5 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.035 mM, at a protein concentration of 2 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0015 mM
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
noncompetitive
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
poor, competitive
19-Azasqualene
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
19-Azasqualene-2,3-epoxide
-
-
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; weak inhibition by 6Z isomer
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; 6Z isomer has no effect on microsomal enzyme
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 6.5 mM
2-Aza-2,3-dihydrosqualene
-
-
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 7.5 mM
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 10 mM
2-Aza-2,3-dihydrosqualene
-
IC50: 2.3 mM, pig microsomes. IC50: 0.15 mM, solubilized enzyme
2-Aza-2,3-dihydrosqualene N-oxide
-
-
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 3.7 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 16 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 7 mM, pig microsomes. IC50: 3.3 mM, solubilized enzyme
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.0025 mM
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.006 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.0035 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.012 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00017 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.1 mM
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0015 mM
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0035 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 0.016 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 280 nM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 750 nM
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
IC50: 160 nM
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(4-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 3 mg/ml
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 2 mg/ml
BIBB 515
-
-
cholesterol
-
an increased cholesterol level suppresses the expression of 2,3-oxidosqualene cyclase
cholesterol
-
an increased cholesterol level suppresses the expression of 2,3-oxidosqualene cyclase
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 1.5 mM
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 14 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 3.2 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 12.5 mM
Iminosqualene
-
-
KCl
-
0-0.1 M: activity decreases with increasing concentration of KCl in the presence of optimal concentrations of Triton X-100
KCl
-
at high concentrations
NEM
-
1 mM, 20% inhibition
NEM
-
following pseudo-first order kinetics
Ro 48-8071
-
IC50: 8.0 nM for the recombinant enzyme, IC50: 6.5 nM for the human liver enzyme
Ro48-8071
-
IC50: 22 nM
S23515
-
-
Squalene maleimide
-
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 13.3 mM
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 5.1 mM
U18666A
-
-
U18666A
-
produce cataract formation
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 92 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 22 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 400 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 161 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 228 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.6 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.3 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 71 nM
additional information
-
antifungal activity of lanosterol synthase inhibitors
-
additional information
-
3-alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl-sn-glycerol has no inhibitory effect
-
additional information
-
a high fat diet reduces OSC expression in the liver
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
-
-
additional information
-
no inhibition: cholesterol
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
no inhibition: EDTA, diethyldicarbonate, phenylmethylsulfonyl fluoride
-
additional information
-
in solutions of low ionic strength the enzyme polymerizes to an inactive form
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0004 - 0.0015
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
0.0015 - 0.0035
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
0.0015 - 0.0035
(18E)-29-methylidene-2,3-oxidosqualene
0.03 - 0.05
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
0.015 - 0.02
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
0.0004 - 0.001
(18Z)-29-methylidene-2,3-oxidosqualene
0.05 - 0.06
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
0.05 - 0.1
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
0.1
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
0.1
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
0.0017 - 0.0074
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
0.00033 - 0.0011
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
0.00036 - 0.0027
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
0.0015 - 0.0025
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
0.012 - 0.025
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
0.0075 - 0.04
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
0.001 - 0.0025
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
0.000143 - 0.000326
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
0.0000318
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
Homo sapiens
-
IC50: 31.8 nM
0.0000157
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
Homo sapiens
-
IC50: 15.7 nM
0.0015 - 0.005
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
0.00005 - 0.001
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
0.06
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
Sus scrofa
-
+ (5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
0.018 - 0.032
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
0.02 - 0.05
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
0.06
(5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
Sus scrofa
-
+ (5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
0.02 - 0.05
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
0.003 - 0.005
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
0.004 - 0.005
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
0.03
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
0.02 - 0.1
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
0.0022 - 0.012
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
0.0004 - 0.001
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
0.03
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
0.000083 - 0.000124
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
0.000112 - 0.000398
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
0.000082
1-(4-iodophenylsulfonyl)-4-(1-(4-pyridyl)piperidon-4-ylcarbonyl)piperazine
Rattus norvegicus
-
IC50: 82 nM
0.000037 - 0.000116
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
0.00002
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
Homo sapiens
-
-
0.000316
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.00004
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000032
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000003
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0005
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000006
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000032
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.000013
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.002511
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.0002
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
Homo sapiens
-
-
0.1
18,19-dihydro-29-methylidene-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.1 mM
0.015 - 0.07
18-heptanor-2,3-oxidosqualene
0.0015 - 0.035
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
0.15 - 10
2-Aza-2,3-dihydrosqualene
3.3 - 16
2-Aza-2,3-dihydrosqualene N-oxide
0.0025 - 0.006
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
0.0035 - 0.012
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
0.00017 - 0.00035
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
0.035 - 0.1
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
0.18
27-norsqualene
Sus scrofa
-
pH 7.4, 37°C, liver microsomes
0.076
29-norsqualene
Sus scrofa
-
pH 7.4, 37°C, liver microsomes
0.0015 - 0.0035
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
0.00028 - 0.016
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
0.00016
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
Rattus norvegicus
-
IC50: 160 nM
0.0000041
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
Homo sapiens
-
IC50: 4.1 nM
0.0000079
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 7.9 nM
0.0000035
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 3.5 nM
0.0000196
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 19.6 nM
0.0000056
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 5.6 nM
0.0000029
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 2.9 nM
0.0000114
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 11.4 nM
0.0000123
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
Homo sapiens
-
IC50: 12.3 nM
0.0000078
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
Homo sapiens
-
IC50: 7.8 nM
0.055
azasqualene alcohol N-oxide
0.00000585
BIBB 515
Homo sapiens
-
-
1.5 - 14
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
3.2 - 12.5
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
0.005
N,N-dimethyl-N-(4-methylenebenzophenonyl)amine
Bos taurus
-
IC50: 0.005 mM
0.059
N-(2-methylenebenzophenonyl)pyridinium
Bos taurus
-
IC50: 0.059 mM
0.016
N-(3-methylenebenzophenonyl)pyridinium bromide
Bos taurus
-
IC50: 0.016 mM
0.00079
N-(4-methylenebenzophenonyl)pyridinium bromide
Bos taurus
-
IC50: 0.00079 mM
0.0002
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
Homo sapiens
-
-
0.000063
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
Homo sapiens
-
-
0.000028
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
Homo sapiens
-
-
0.0025
N-[3-(1,1'-biphenyl-4-yloxy)propyl]-N,N-dimethylamine
Rattus norvegicus
-
IC50: 2500 nM
0.0000065 - 0.000008
Ro 48-8071
0.000022
Ro48-8071
Bos taurus
-
IC50: 22 nM
5.1 - 13.3
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
0.000022 - 0.0004
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
0.000161 - 0.000228
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
0.0000063
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 6.3 nM
0.0000046
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 4.6 nM
0.0000041
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 4.1 nM
0.0000062
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 6.2 nM
0.0000054
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
Homo sapiens
-
IC50: 5.4 nM
0.0000019
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
Homo sapiens
-
IC50: 1.9 nM
0.0000067
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
Homo sapiens
-
IC50: 6.7 nM
0.0000225
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
Homo sapiens
-
IC50: 22.5 nM
0.000049
[5-(4-(4-chloro-benzoyl)-3-fluoro-phenoxy)-pentyl]-methyl-propyl-ammonium fumarate
Rattus norvegicus
-
IC50: 49 nM
0.0000087
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 8.7 nM
0.0000353
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
Homo sapiens
-
IC50: 35.3 nM
0.00009
{4-[4-(4,5-Dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone
Rattus norvegicus
-
IC50: 90 nM, complete inhibition at 0.001 nM
0.0000043 - 0.000071
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
0.0004
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
Sus scrofa
-
IC50: 0.0004 mM
0.0015
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
Saccharomyces cerevisiae
-
IC50: 0.0015 mM
0.0015
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
Saccharomyces cerevisiae
-
IC50: 0.0015 mM, irreversible
0.0035
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
Sus scrofa
-
IC50: 0.0035 mM, irreversible
0.0015
(18E)-29-methylidene-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: 0.0015 mM
0.0035
(18E)-29-methylidene-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.0035 mM
0.03
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: 0.03 mM
0.05
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.05 mM
0.015
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
Saccharomyces cerevisiae
-
IC50: 0.015 mM
0.02
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
Sus scrofa
-
IC50: 0.02 mM
0.0004
(18Z)-29-methylidene-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.0004 mM
0.001
(18Z)-29-methylidene-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: 0.001 mM
0.05
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: 0.05 mM
0.06
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.06 mM
0.05
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
Saccharomyces cerevisiae
-
IC50: 0.05 mM
0.1
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
Sus scrofa
-
IC50: 0.1 mM
0.1
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
Sus scrofa
-
IC50: above 0.1 mM
0.1
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: above 0.1 mM
0.1
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
Sus scrofa
-
IC50: above 0.1 mM
0.1
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: above 0.1 mM
0.0017
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
Pneumocystis carinii
-
-
0.0045
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
Homo sapiens
-
-
0.0074
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
Trypanosoma cruzi
-
-
0.00033
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
Pneumocystis carinii
-
-
0.00045
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
Saccharomyces cerevisiae
-
-
0.00047
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
Trypanosoma cruzi
-
-
0.0011
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
Homo sapiens
-
-
0.00036
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
Pneumocystis carinii
-
-
0.00085
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
Homo sapiens
-
-
0.00178
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
Saccharomyces cerevisiae
-
-
0.0027
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
Trypanosoma cruzi
-
-
0.0015
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
Saccharomyces cerevisiae
-
IC50: 0.0015 mM
0.0025
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
Sus scrofa
-
IC50: 0.0025 mM
0.012
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
Sus scrofa
-
IC50: 0.012 mM
0.025
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
Saccharomyces cerevisiae
-
IC50: 0.025 mM
0.0075
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
Sus scrofa
-
IC50: 0.0075 mM
0.04
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
Saccharomyces cerevisiae
-
IC50: 0.04 mM
0.001
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
Sus scrofa
-
IC50: 0.001 mM
0.0025
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
Saccharomyces cerevisiae
-
IC50: 0.0025 mM
0.000143
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Homo sapiens
-
IC50: 143 nM
0.000326
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Rattus norvegicus
-
IC50: 326 nM
0.0015
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
Saccharomyces cerevisiae
-
IC50: 0.0015 mM
0.005
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
Sus scrofa
-
IC50: 0.005 mM
0.00005
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
Saccharomyces cerevisiae
-
IC50: 0.00005 mM
0.001
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
Sus scrofa
-
IC50: 0.001 mM
0.018
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
Saccharomyces cerevisiae
-
IC50: 0.018 mM
0.032
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
Sus scrofa
-
IC50: 0.032 mM
0.02
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
Sus scrofa
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
0.05
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
Saccharomyces cerevisiae
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
0.02
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
Sus scrofa
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
0.05
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
Saccharomyces cerevisiae
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
0.003
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
Candida albicans
-
IC50: 0.003 mM, at a protein concentration of 3 mg/ml
0.0048
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
Rattus norvegicus
-
IC50: 0.0048 mM, at a protein concentration of 5 mg/ml
0.005
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
Sus scrofa
-
IC50: 0.005 mM, at a protein concentration of 1 mg/ml
0.005
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
Saccharomyces cerevisiae
-
IC50: 0.005 mM, at a protein concentration of 2 mg/ml
0.004
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
Sus scrofa
-
IC50: 0.004 mM
0.005
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
Saccharomyces cerevisiae
-
IC50: 0.005 mM
0.03
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
Sus scrofa
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.03
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
Saccharomyces cerevisiae
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.02
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
Rattus norvegicus
-
IC50: above 0.02 mM, at a protein concentration of 5 mg/ml
0.1
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
Saccharomyces cerevisiae
-
IC50: above 0.1 mM, at a protein concentration of 2 mg/ml
0.1
(6Z)-10-aza-10,11-dihydrosqualene-2,3-epoxide
Candida albicans
-
IC50: above 0.1 mM, at a protein concentration of 3 mg/ml
0.0022
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
Sus scrofa
-
IC50: 0.0022 mM
0.012
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
Saccharomyces cerevisiae
-
IC50: 0.012 mM
0.0004
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
Sus scrofa
-
IC50: 0.0004 mM
0.001
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
Saccharomyces cerevisiae
-
IC50: 0.001 mM
0.03
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
Sus scrofa
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.03
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
Saccharomyces cerevisiae
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.000083
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
Homo sapiens
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
0.000124
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
Rattus norvegicus
-
IC50: 124 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
0.000112
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Homo sapiens
-
IC50: 112 nM
0.000398
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Rattus norvegicus
-
76% inhibition at 0.001 mM, IC50: 398 nM
0.000037
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Homo sapiens
-
IC50: 37 nM
0.000116
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
Rattus norvegicus
-
complete inhibition at 0.001 mM, IC50: 116 nM
0.015
18-heptanor-2,3-oxidosqualene
Sus scrofa
-
IC50: 0.015 mM
0.07
18-heptanor-2,3-oxidosqualene
Saccharomyces cerevisiae
-
IC50: 0.07 mM
0.0015
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
Sus scrofa
-
IC50: 0.0015 mM
0.0075
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
Rattus norvegicus
-
IC50: 0.0075 mM, protein concentration of 5 mg/ml
0.022
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
Candida albicans
-
IC50: 0.022 mM, protein concentration of 3 mg/ml
0.035
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
Saccharomyces cerevisiae
-
IC50: 0.035 mM, at a protein concentration of 2 mg/ml
0.15
2-Aza-2,3-dihydrosqualene
Sus scrofa
-
IC50: 2.3 mM, pig microsomes. IC50: 0.15 mM, solubilized enzyme
6.5
2-Aza-2,3-dihydrosqualene
Candida albicans
-
IC50: 6.5 mM
7.5
2-Aza-2,3-dihydrosqualene
Rattus norvegicus
-
IC50: 7.5 mM
10
2-Aza-2,3-dihydrosqualene
Saccharomyces cerevisiae
-
IC50: 10 mM
3.3
2-Aza-2,3-dihydrosqualene N-oxide
Sus scrofa
-
IC50: 7 mM, pig microsomes. IC50: 3.3 mM, solubilized enzyme
3.7
2-Aza-2,3-dihydrosqualene N-oxide
Rattus norvegicus
-
IC50: 3.7 mM
16
2-Aza-2,3-dihydrosqualene N-oxide
Saccharomyces cerevisiae
-
IC50: 16 mM
0.0025
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
Saccharomyces cerevisiae
-
IC50: 0.0025 mM
0.006
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
Sus scrofa
-
IC50: 0.006 mM
0.0035
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
Saccharomyces cerevisiae
-
IC50: 0.0035 mM
0.012
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
Sus scrofa
-
IC50: 0.012 mM
0.00017
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
Saccharomyces cerevisiae
-
IC50: 0.00017 mM
0.00035
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
Sus scrofa
-
IC50: 0.00035 mM
0.035
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
Saccharomyces cerevisiae
-
IC50: 0.035 mM
0.1
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
Sus scrofa
-
IC50: 0.1 mM
0.0015
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
Saccharomyces cerevisiae
-
IC50: 0.0015 mM
0.0035
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
Sus scrofa
-
IC50: 0.0035 mM
0.00028
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
Trypanosoma brucei
-
IC50: 280 nM
0.00075
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
Trypanosoma cruzi
-
IC50: 750 nM
0.016
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
Pneumocystis carinii
-
IC50: 0.016 mM
0.055
azasqualene alcohol N-oxide
Saccharomyces cerevisiae
-
IC50: 0.055 mM, at a protein concentration of 2 mg/ml
0.055
azasqualene alcohol N-oxide
Candida albicans
-
IC50: 0.055 mM, at a protein concentration of 3 mg/ml
1.5
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
Rattus norvegicus
-
IC50: 1.5 mM
14
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
Saccharomyces cerevisiae
-
IC50: 14 mM
3.2
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
Rattus norvegicus
-
IC50: 3.2 mM
12.5
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
Saccharomyces cerevisiae
-
IC50: 12.5 mM
0.0000065
Ro 48-8071
Homo sapiens
-
IC50: 6.5 nM for the human liver enzyme
0.000008
Ro 48-8071
Homo sapiens
-
IC50: 8.0 nM for the recombinant enzyme
5.1
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
Rattus norvegicus
-
IC50: 5.1 mM
13.3
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
Candida albicans
-
IC50: 13.3 mM
0.000022
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
Trypanosoma brucei
-
IC50: 22 nM
0.000092
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
Pneumocystis carinii
-
IC50: 92 nM
0.0004
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
Trypanosoma cruzi
-
IC50: 400 nM
0.000161
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Homo sapiens
-
IC50: 161 nM
0.000228
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
Rattus norvegicus
-
IC50: 228 nM
0.0000043
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
Trypanosoma brucei
-
IC50: 4.3 nM
0.0000046
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
Pneumocystis carinii
-
IC50: 4.6 nM
0.000071
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
Trypanosoma cruzi
-
IC50: 71 nM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
H232S
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
H232T
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
N478H/V482I
-
change of amino acids crucial for specificity to the cycloartenol synthase type. Mutant produces 4% lanosterol, 83% parkeol, and 13% cycloartenol from substrate (S)-2,3-epoxysqualene
D139N/G189A/Q481R
induces cataracts in rats, produces only 39% of the lanosterol produced by wild-type
H469-C472del
deletion allele, inactive
C457D
-
less active than the wild-type
C457D/A525C
-
similar activity as the wild-type
C457D/E526A
-
decrease in enzyme functionality
C457D/E526C
-
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
C457D/E526D
-
no effect on catalytic avtivity
C457D/E526Q
-
no effect on catalytic avtivity
C457G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
C457G/T509G
-
site-directed mutagenesis, the mutations disrupt the pre-existing H-bond to the protonating Asp456 and the intrinsic His234-Tyr510 H-bond network, respectively, and generates achilleol A as the major product
C703D
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703G
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703H
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703I
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703N
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703S
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703T
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703V
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
F445C
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 69% lanosterol, 13% parkeol, 8% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445D
-
produces 21% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 11% parkeol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445M
-
produces 7% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 65% lanosterol, 18% parkeol, 10% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445N
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 9% parkeol, 18% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445T
-
produces 49% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 46% lanosterol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F699A/C703I
-
site-directed mutagenesis, inactive mutant
F699C/I705F
-
the mutant is inactive
F699H
-
the mutant produces lanosterol (13%), protosta-13(17)-dien-3beta-ol (70%), and (17Z)-protosta-17(20),24-dien-3beta-ol (17%)
F699I
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699L
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699M/C703I
-
site-directed mutagenesis, inactive mutant
F699M/I705F
-
the mutant produces 53% lanosterol, 17% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 12% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 15% protosta-13(17),24-dien-3beta-ol, and 3% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699N
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
F699P
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699T/C703I
-
site-directed mutagenesis, different oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are isolated from the mutant
F699T/I105F
-
the mutant produces 36% lanosterol, 45% protosta-13(17),24-dien-3beta-ol, 7% 17alpha-protosta-20,24-dien-3beta-ol, and 12% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699X
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
H234A
-
products are 17% protosta-12,24-dien-3beta-ol, 13% protosta-20,24-dien-3beta-ol, 30% lanosterol, 40% parkeol
H234C
-
products are 7% protosta-12,24-dien-3beta-ol, 4% protosta-20,24-dien-3beta-ol, 67% lanosterol, 22% parkeol
H234D
-
products are 58% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 12% parkeol
H234E
-
products are 49% lanosterol, 51% parkeol
H234F
-
products are 66% achilleol A, 14% lanosterol, 20% parkeol
H234G
-
products are 29% protosta-12,24-dien-3beta-ol, 7% protosta-20,24-dien-3beta-ol, 17% lanosterol, 47% parkeol
H234I
-
products are 70% lanosterol, 30% parkeol
H234K
-
no catalytic activity
H234L
-
products are 39% lanosterol, 31% parkeol, 30% iso-malabarica-14(16),17,21-trien-3beta-ol
H234M
-
products are 17% achilleol A, 10% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 40% parkeol
H234N
-
products are 23% protosta-12,24-dien-3beta-ol, 14% protosta-20,24-dien-3beta-ol, 27% lanosterol, 10% parkeol, 26% iso-malabarica-14(16),17,21-trien-3beta-ol
H234P
-
products are 64% lanosterol, 36% parkeol
H234Q
-
product is 100% lanosterol, like wild-type
H234R
-
no catalytic activity
H234S
-
product is 100% protosta-12,24-dien-3beta-ol
H234T
-
product is 100% parkeol
H234V
-
products are 42% lanosterol, 58% parkeol
H234W
-
product is 100% parkeol
H234W/Y510V
-
the mutant produces achilleol A, (13H)-isomalabarica-14(26),17E,21-trien-3beta-ol, and lanosterol at a 2:8:90 ratio from (S)-2,3-oxidosqualene
H234Y
-
products are 14% achilleol A, 26% protosta-12,24-dien-3beta-ol, 51% lanosterol, 9% parkeol
H234Y/Y510A
-
the mutant produces lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
I705A
-
the mutant produces 78% lanosterol, 13% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 8% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 0.3% protosta-13(17),24-dien-3beta-ol, and 0.7% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705C
-
the mutant produces 72% lanosterol, 16% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 11.7% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 0.3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705D
-
the mutant produces 37% lanosterol, 32% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 30% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705F
-
the mutant produces 25% lanosterol, 21(13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, 6% 17alpha-protosta-20,24-dien-3beta-ol, 42% 17alpha-protosta-20(22),24-dien-3beta-ol from, and 6% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705G
-
the mutant produces 35% lanosterol, 23% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 34% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 6% protosta-13(17),24-dien-3beta-ol, 1% 17alpha-protosta-20(22),24-dien-3beta-ol and 1% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705K
-
the mutant produces 12% lanosterol, 26.5% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 53.1% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 7.6% protosta-13(17),24-dien-3beta-ol, and 0.8% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705L
-
the mutant produces 100% lanosterol from (3S)-2,3-oxidosqualene (wild-type activity)
I705M
-
the mutant produces 88% lanosterol, 6% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 6% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705N
-
the mutant produces 19% lanosterol, 41% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 37% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705P
-
the mutant produces 81.9% lanosterol, 0.1% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705Q
-
the mutant produces 25% lanosterol, 39% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 31% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 5% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705S
-
the mutant produces 12% lanosterol, 42% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 44% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 1% protosta-13(17),24-dien-3beta-ol, and 1%protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705T
-
the mutant produces 22% lanosterol, 36% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 41% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705V
-
the mutant produces 75% lanosterol, 10% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme produng exclusively achilleol A as product
Q450H/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, and protosta-16,24-dien-3beta-ol
T384Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol
T384Y/Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and very low amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T384Y/Q450H/V454I
-
site-directed mutagenesis, the mutant produces exclusively reaction intermediate parkeol but not lanosterol as the sole end product
T384Y/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and lower amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T509G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
V454A
-
results in the production of an additional truncated monocyclic achilleol A
V454G
-
results in the production of an additional truncated monocyclic achilleol A
V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly lanosterol and a low amount of (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol
W232A
-
products are 18.1% protosta-12,24-dien-3beta-ol, 47.1% lanosterol, 34.8% parkeol
W232C
-
products are 18% protosta-12,24-dien-3beta-ol, 31.8% lanosterol, 50.2% parkeol
W232D
-
products are 7.9% protosta-12,24-dien-3beta-ol, 84.8% lanosterol, 7.3% parkeol
W232E
-
products are 14% protosta-12,24-dien-3beta-ol, 49.2% lanosterol, 36.8% parkeol
W232F
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17,2% parkeol
W232G
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17.2% parkeol
W232H
-
products are 27.8% protosta-12,24-dien-3beta-ol, 35% lanosterol, 37.2% parkeol
W232I
-
products are 23.5% protosta-12,24-dien-3beta-ol, 33% lanosterol, 43.5% parkeol
W232K
-
no catalytic activity
W232L
-
products are 14.5% protosta-12,24-dien-3beta-ol, 27.8% lanosterol, 57.7% parkeol
W232M
-
products are 10.9% protosta-12,24-dien-3beta-ol, 40.6% lanosterol, 48.5% parkeol
W232N
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59.5% lanosterol, 29.8% parkeol
W232P
-
products are 4.4% protosta-12,24-dien-3beta-ol, 82.9% lanosterol, 12.7% parkeol
W232Q
-
products are 24.6% protosta-12,24-dien-3beta-ol, 32.1% lanosterol, 43.3% parkeol
W232R
-
no catalytic activity
W232S
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59% lanosterol, 30.3% parkeol
W232T
-
products are 14.3% protosta-12,24-dien-3beta-ol, 61.7% lanosterol, 24% parkeol
W232V
-
products are 19.3% protosta-12,24-dien-3beta-ol, 34% lanosterol, 46.7% parkeol
W232Y
-
products are 4.2% protosta-12,24-dien-3beta-ol, 94.2% lanosterol, 1.6% parkeol
W587F
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
W587Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510C
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510F
-
produces lanosterol and isomalabaricatrienol in a 95:5 ratio in strain RXY6, while in strain SMY8, the ratio is 10:90
Y510L
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510S
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y707A
-
the mutant produces 18.9% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 56.9% lanosterol, 19.9% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707C
-
the mutant produces 6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 47.1% lanosterol, 42.6% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707D
-
the mutant produces 21.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 67.3% lanosterol, 7.6% 9beta-lanosta-7,24-dien-3beta-ol, and 3.3% parkeol from (S)-2,3-oxidosqualene
Y707E
-
the mutant produces 12.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 70.8% lanosterol, 10.5% 9beta-lanosta-7,24-dien-3beta-ol, and 6.4% parkeol from (S)-2,3-oxidosqualene
Y707F
-
the mutant produces 89.2% lanosterol, 3.1% parkeol, and 7.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707G
-
the mutant produces 28.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 48.2% lanosterol, 16.3% 9beta-lanosta-7,24-dien-3beta-ol, and 7.2% parkeol from (S)-2,3-oxidosqualene
Y707H
-
the mutant produces 83.6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.7% lanosterol, 6.2% 9beta-lanosta-7,24-dien-3beta-ol, and 5.5% parkeol from (S)-2,3-oxidosqualene
Y707I
-
the mutant produces 87.9% lanosterol and 12.1% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707K
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707L
-
the mutant produces 85.3% lanosterol and 14.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707M
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707N
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707P
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707Q
-
the mutant produces 82% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.3% lanosterol, and 13.7% parkeol from (S)-2,3-oxidosqualene
Y707S
-
the mutant produces 21.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 42.9% lanosterol, 20.5% 9beta-lanosta-7,24-dien-3beta-ol, and 15.3% parkeol from (S)-2,3-oxidosqualene
Y707T
-
the mutant produces 9.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 65.1% lanosterol, 13.5% 9beta-lanosta-7,24-dien-3beta-ol, and 11.6% parkeol from (S)-2,3-oxidosqualene
Y707V
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707W
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707X
-
the mutant produces (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, in addition to lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
C457D
-
less active than the wild-type
-
C457D/E526A
-
decrease in enzyme functionality
-
C457D/E526C
-
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
-
C457D/E526D
-
no effect on catalytic avtivity
-
C457D/E526Q
-
no effect on catalytic avtivity
-
F699I
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699L
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699N
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
-
F699T
-
the mutant produces lanosterol (less than 0.2%) and protosta-13(17)-dien-3beta-ol (above 99.8%)
-
F699X
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
-
F699C
-
inactive
F699C
-
the mutant is inactive
F699M
-
the mutant produces lanosterol (13%), (17Z)-protosta-17(20),24-dien-3beta-ol (46%), protosta-13(17)-dien-3beta-ol (70%), malabarica-14E,17E,21-trien-3beta-ol (7%), 17alpha-protosta-20,24-dien-3beta-ol (1%), (17Z)-protosta-17(20),24-dien-3beta-ol (10%), (13alphaH)-isomalabarica-14E,17E,21-dien-3 beta-ol (17%), and (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol (18%)
F699M
-
the mutant produces 1% lanosterol, 17% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 18% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 46% protosta-13(17),24-dien-3beta-ol, 1% 17alpha-protosta-20,24-dien-3beta-ol, 10% protosta-17(20),24-dien-3beta-ol and 7% malabarica-14E,17E,21-trien-3beta-ol from (3S)-2,3-oxidosqualene
F699T
-
the mutant produces novel protosta-13(17),24-dien-3beta-ol as the sole truncated rearrangement product from (S)-2,3-oxidosqualene
F699T
-
the mutant produces protosta-13(17),24-dien-3beta-ol from (S)-2,3-oxidosqualene
F699T
-
the mutant produces lanosterol (less than 0.2%) and protosta-13(17)-dien-3beta-ol (above 99.8%)
F699T
-
the mutant produces less than 0.2% lanosterol and more than 99.8% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
H234W/Y510W
-
mutant produces achilleol A from (S)-2,3-oxidosqualene
H234W/Y510W
-
site-directed mutagenesis, the double mutation alters the ERG7 function to achilleol A synthase activity and generates achilleol A as the sole product
Y510A
-
produces lanosterol, parkeol and achilleol A in a 39:34:27 ratio
Y510A
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510H
-
incomplete cyclization, produces achilleol (45%), lanosterol (42%), parkeol (9%), and isomalabaricatrienol (4%)
Y510H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510K
-
inactive
Y510K
-
fails to maintain cell viability in the absence of ergosterol, in the presence of ergosterol the mutant produces achilleol A and camelliol C in a ratio of 86:14
Y510K
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510W
-
inactive
Y510W
-
fails to maintain cell viability in the absence of ergosterol, in the presence of ergosterol the mutant produces achilleol A and camelliol C in a ratio of 96:4
Y510W
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
additional information
no visible morphological phenotypes are observed in enzyme disruption mutant and no differences in sterol profiles between the wild type and mutant are detected. Enzyme gene complements enzyme-deficient yeast strain
additional information
-
an oxidosqualene:protostadienol cyclase mutant in which the C-terminal residues 702APPGGMR708 are replaced with 702NKSCAIS708 efficiently produces a 1:1 mixture of lanosterol and parkeol
additional information
-
only polar side-chain group substitutions of F445 genetically complement yeast viability and produce spatially related product diversity
additional information
overexpression of Arabidopsis thaliana AtLAS in leaves via transformation by Agrobacterium tumefaciens strain EHA 105, where the endogenic StLAS-like is not expressed, results in increased steroidal glycoalkaloid level and reduced phytosterol level in the leaves, while the steroidal glycoalkaloid level in the tuber flesh is reduced
additional information
-
overexpression of Arabidopsis thaliana AtLAS in leaves via transformation by Agrobacterium tumefaciens strain EHA 105, where the endogenic StLAS-like is not expressed, results in increased steroidal glycoalkaloid level and reduced phytosterol level in the leaves, while the steroidal glycoalkaloid level in the tuber flesh is reduced
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Willett, J.D.; Sharpless, K.B.; Lord, K.E.; van Tamelen, E.E.; Clayton, R.B.
Squalene-2,3-oxide, an intermediate in the enzymatic conversion of squalene to lanosterol and cholesterol
J. Biol. Chem.
242
4182-4191
1967
Rattus norvegicus
brenda
Dean, P.D.G.; Ortiz de Montellano, P.R.; Bloch, K.; Corey, E.J.
A soluble 2,3-oxidosqualene sterol cyclase
J. Biol. Chem.
242
3014-3015
1967
Sus scrofa
brenda
Yamamoto, S.; Lin, K.; Bloch, K.
Some properties of the microsomal 2,3-oxidosqualene sterol cyclase
Proc. Natl. Acad. Sci. USA
63
110-117
1969
Sus scrofa
brenda
Balliano, G.; Milla, P.; Ceruti, M.; Viola, F.; Carrano, L.; Cattel, L.
Differential inhibition of fungal oxidosqualene cyclase by 6E and 6Z isomers of 2,3-epoxy-10-aza-10,11-dihydrosqualene
FEBS Lett.
320
203-206
1993
Saccharomyces cerevisiae, Candida albicans
brenda
Shi, Z.; Buntel, C.J.; Griffin, J.H.
Isolation and characterization of the gene encoding 2,3-oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae
Proc. Natl. Acad. Sci. USA
91
7370-7374
1994
Saccharomyces cerevisiae
brenda
Tabacik, C.; Descomps, B.; Crastles de Paulet, A.
The squalene epoxide-cyclase activity of human term placenta
FEBS Lett.
34
238-242
1973
Homo sapiens
brenda
Saat, Y.A.; Bloch, K.E.
Effect of a supernatant protein on microsomal squalene epoxidase and 2,3-oxidosqualene-lanosterol cyclase
J. Biol. Chem.
251
5155-5160
1976
Rattus norvegicus
brenda
Chang, T.Y.; Schiavoni, E.S.; McCrae, K.R.; Nelson, J.A.; Spencer, T.A.
Inhibition of cholesterol biosynthesis in Chinese hamster ovary cells by 4,4,10beta-trimethyl-trans-decal-3beta-ol
J. Biol. Chem.
254
11258-11263
1979
Mesocricetus auratus
brenda
Chen, H.W.; Leonard, D.A.
Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells
J. Biol. Chem.
259
8156-8162
1984
Mus musculus
brenda
Taton, M.; Benveniste, P.; Rahier, A.
N-[(1,5,9)-Trimethyl-decyl]-4alpha,10-dimethyl-8-aza-trans-decal-3beta-ol a novel potent inhibitor of 2,3-oxidosqualene cycloartenol and lanosterol cyclases
Biochem. Biophys. Res. Commun.
138
764-770
1986
Rattus norvegicus
brenda
Corey, E.J.; Matsuda, S.P.T.; Bartel, B.
Molecular cloning, characterization, and overexpression of ERG7, the Saccharomyces cerevisiae gene encoding lanosterol synthase
Proc. Natl. Acad. Sci. USA
91
2211-2215
1994
Saccharomyces cerevisiae
brenda
Duriatti, A.; Schuber, F.
Partial purification of 2,3-oxidosqualene-lanosterol cyclase from hog-liver. Evidence for functional thiol residue
Biochem. Biophys. Res. Commun.
151
1378-1385
1988
Sus scrofa
brenda
Balliano, G.; Viola, F.; Ceruti, M.; Cattel, L.
Inhibition of sterol biosynthesis in Saccharomyces cerevisiae by N,N-diethylazasqualene and derivatives
Biochim. Biophys. Acta
959
9-19
1988
Saccharomyces cerevisiae
brenda
Rohmer, M.; Bouvier, P.; Ourisson, G.
Non-specific lanosterol and hopanoid biosynthesis by a cell-free system from the bacterium Methylococcus capsulatus
Eur. J. Biochem.
112
557-560
1980
Methylococcus capsulatus
brenda
Hoshino, T.; Williams, H.J.; Chung, Y.; Ian Scott, A.
Partial purification and characterization of oxidosqualene-lanosterol cyclase from baker's yeast
Tetrahedron
47
5925-5932
1991
Saccharomyces cerevisiae
-
brenda
Corey, E.J.; Matsuda, S.P.T.
Purification of the 2,3-oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae
J. Am. Chem. Soc.
113
8172-8174
1991
Saccharomyces cerevisiae
-
brenda
Balliano, G.; Viola, F.; Ceruti, M.; Cattel, L.
Characterization and partial purification of squalene-2,3-oxide cyclase from Saccharomyces cerevisiae
Arch. Biochem. Biophys.
293
122-129
1992
Saccharomyces cerevisiae
brenda
Kelly, R.; Miller, S.M.; Lai, M.H.; Kirsch, D.R.
Cloning and characterization of the 2,3-oxidosqualene cyclase-coding gene of Candida albicans
Gene
87
177-183
1990
Candida albicans
brenda
Abad, J.L.; Guardiola, M.; Casas, J.; Sanchez-Baeza, F.; Messeguer, A.
2,3,18,19-Dioxidosqualene stereoisomers: characterization and activity as inhibitors of purified pig liver 2,3-oxidosqualene-lanosterol cyclase
J. Org. Chem.
61
7603-7607
1996
Sus scrofa
brenda
Cattel, L.; Ceruti, M.; Balliano, G.; Viola, F.; Grosa, G.; Rocco, F.; Brusa, P.
2,3-Oxidosqualene cyclase: from azasqualenes to new site-directed inhibitors
Lipids
30
235-246
1995
Saccharomyces cerevisiae, Candida albicans, Rattus norvegicus, Sus scrofa
brenda
Viola, F.; Brusa, P.; Balliano, G.; Ceruti, M.; Boutaud, O.; Schuber, F.; Cattel, L.
Inhibition of 2,3-oxidosqualene cyclase and sterol biosynthesis by 10- and 19-azasqualene derivatives
Biochem. Pharmacol.
50
787-796
1995
Saccharomyces cerevisiae, Candida albicans, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Jolidon, S.; Polak, A.M.; Guerry, P.; Hartman, P.G.
Inhibitors of 2,3-oxidosqualene lanosterol-cyclase as potential antifungal agents
Biochem. Soc. Trans.
18
47-48
1990
Candida albicans, Rattus norvegicus
brenda
Kusano, M.; Abe, I.; Sankawa, U.; Ebizuka, Y.
Purification and some properties of squalene 2,3-epoxide: lanosterol cyclase from rat liver
Chem. Pharm. Bull.
39
239-241
1991
Rattus norvegicus
brenda
Wannamaker, M.W.; Waid, P.P.; van Sickle, W.A.; McCarthy, J.R.; Wilson, P.K.; Schatzman, G.L.; Moore, W.R.
N-(1-Oxododecyl)-4alpha,10-dimethyl-8-aza-trans-decal-3beta-ol: a potent competitive inhibitor of 2,3-oxidosqualene cyclase
J. Med. Chem.
35
3581-3583
1992
Rattus norvegicus
brenda
Barth, M.M.; Binet, J.L.; Thomas, D.M.; de Fornel, D.C.; Samreth, S.; Schuber, F.J.; Renaut, P.P.
Structural and stereoelectronic requirements for the inhibition of mammalian oxidosqualene cyclase by substituted isoquinoline derivatives
J. Med. Chem.
39
2302-2312
1996
Rattus norvegicus
brenda
Stach, D.; Zheng, Y.F.; Perez, A.L.; Oehlschlager, A.C.; Abe, I.; Prestwich, G.D.; Hartman, P.G.
Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase
J. Med. Chem.
40
201-209
1997
Candida albicans, Rattus norvegicus, Sus scrofa
brenda
Ceruti, M.; Rocco, F.; Viola, F.; Balliano, G.; Milla, P.; Arpicco, S.; Cattel, L.
9-Methylidine-2,3-oxidosqualene derivatives as stereospecific mechanism-based inhibitors of liver and yeast oxidosqualene cyclase
J. Med. Chem.
41
540-554
1998
Saccharomyces cerevisiae, Sus scrofa
brenda
Moore, W.R.; Schatzman, G.L.
Purification of 2,3-oxidosqualene cyclase from rat liver
J. Biol. Chem.
267
22003-22006
1992
Rattus norvegicus
brenda
Abe, I.; Prestwich, G.D.
Molecular cloning, characterization, and functional expression of rat oxidosqualene cyclase cDNA
Proc. Natl. Acad. Sci. USA
92
9274-9278
1995
Rattus norvegicus
brenda
Astruc, M.; Tabacik, C.; Descomps, B.; Crastes de Paulet, A.
Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues
Biochim. Biophys. Acta
487
204-211
1977
Rattus norvegicus
brenda
Ceruti, M.; Balliano, G.; Rocco, F.; Milla, P.; Arpicco, S.; Cattel, L.; Viola, F.
Vinyl sulfide derivatives of truncated oxidosqualene as selective inhibitors of oxidosqualene and squalene-hopene cyclases
Lipids
36
629-636
2001
Saccharomyces cerevisiae, Sus scrofa
brenda
Wu, T.K.; Huang, C.Y.; Ko, C.Y.; Chang, C.H.; Chen, Y.J.; Liao, H.K.
Purification, tandem mass characterization, and inhibition studies of oxidosqualene-lanosterol cyclase enzyme from bovine liver
Arch. Biochem. Biophys.
421
42-53
2004
Bos taurus
brenda
Ruf, A.; Muller, F.; D'Arcy, B.; Stihle, M.; Kusznir, E.; Handschin, C.; Morand, O.H.; Thoma, R.
The monotopic membrane protein human oxidosqualene cyclase is active as monomer
Biochem. Biophys. Res. Commun.
315
247-254
2004
Homo sapiens
brenda
Viola, F.; Balliano, G.; Milla, P.; Cattel, L.; Rocco, F.; Ceruti, M.
Stereospecific syntheses of trans-vinyldioxidosqualene and 3-hydroxysulfide derivatives, as potent and time-dependent 2,3-oxidosqualene cyclase inhibitors
Bioorg. Med. Chem.
8
223-232
2000
Saccharomyces cerevisiae, Sus scrofa
brenda
Cattel, L.; Ceruti, M.
Inhibitors of 2,3-oxidosqualene cyclase as tools for studying the mechanism and function of the enzyme
Crit. Rev. Biochem. Mol. Biol.
33
353-373
1998
Candida albicans, Canis lupus familiaris, Rattus norvegicus, Saccharomyces cerevisiae, Sus scrofa
brenda
Ceruti, M.; Viola, F.; Balliano, G.; Milla, P.; Roma, G.; Grossi, G.; Rocco, F.
Synthesis of (E)- and (Z)-29-methylidyne-2,3-oxidosqualene derivatives as inhibitors of liver and yeast oxidosqualene cyclase
J. Chem. Soc. Perkin Trans.
1
1477-1486
2002
Saccharomyces cerevisiae, Sus scrofa
-
brenda
Brown, G.R.; Hollinshead, D.M.; Stokes, E.S.; Clarke, D.S.; Eakin, M.A.; Foubister, A.J.; Glossop, S.C.; Griffiths, D.; Johnson, M.C.; McTaggart, F.; Mirrlees, D.J.; Smith, G.J.; Wood, R.
Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles
J. Med. Chem.
42
1306-1311
1999
Homo sapiens, Rattus norvegicus
brenda
Brown, G.R.; Hollinshead, D.M.; Stokes, E.S.; Waterson, D.; Clarke, D.S.; Foubister, A.J.; Glossop, S.C.; McTaggart, F.; Mirrlees, D.J.; Smith, G.J.; Wood, R.
A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase
J. Med. Chem.
43
4964-4972
2000
Homo sapiens, Rattus norvegicus
brenda
Dehmlow, H.; Aebi, J.D.; Jolidon, S.; Ji, Y.H.; von der Mark, E.M.; Himber, J.; Morand, O.H.
Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors
J. Med. Chem.
46
3354-3370
2003
Homo sapiens
brenda
Hinshaw, J.C.; Suh, D.Y.; Garnier, P.; Buckner, F.S.; Eastman, R.T.; Matsuda, S.P.; Joubert, B.M.; Coppens, I.; Joiner, K.A.; Merali, S.; Nash, T.E.; Prestwich, G.D.
Oxidosqualene cyclase inhibitors as antimicrobial agents
J. Med. Chem.
46
4240-4243
2003
Pneumocystis carinii, Rattus norvegicus, Trypanosoma brucei, Trypanosoma cruzi
brenda
Joubert, B.M.; Buckner, F.S.; Matsuda, S.P.T.
Trypanosome and animal lanosterol synthases use different catalytic motifs
Org. Lett.
3
1957-1960
2001
Trypanosoma cruzi (Q964Q1), Trypanosoma cruzi
brenda
Venteclef, N.; Guillard, R.; Issandou, M.
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity
Biochem. Pharmacol.
69
1041-1048
2005
Macaca fascicularis, Homo sapiens, Rattus norvegicus
brenda
Sakano, Y.; Mutsuga, M.; Tanaka, R.; Suganuma, H.; Inakuma, T.; Toyoda, M.; Goda, Y.; Shibuya, M.; Ebizuka, Y.
Inhibition of human lanosterol synthase by the constituents of Colocasia esculenta (taro)
Biol. Pharm. Bull.
28
299-304
2005
Homo sapiens
brenda
Tanaka, R.; Sakano, Y.; Nagatsu, A.; Shibuya, M.; Ebizuka, Y.; Goda, Y.
Synthesis of digalactosyl diacylglycerols and their structure-inhibitory activity on human lanosterol synthase
Bioorg. Med. Chem. Lett.
15
159-162
2005
Homo sapiens
brenda
Wu, T.K.; Chang, C.H.
Enzymatic formation of multiple triterpenes by mutation of tyrosine 510 of the oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae
ChemBioChem
5
1712-1715
2004
Saccharomyces cerevisiae
brenda
Oliaro-Bosso, S.; Schulz-Gasch, T.; Balliano, G.; Viola, F.
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach
ChemBioChem
6
2221-2228
2005
Saccharomyces cerevisiae, Saccharomyces cerevisiae SMY8
brenda
Mori, M.; Li, G.; Abe, I.; Nakayama, J.; Guo, Z.; Sawashita, J.; Ugawa, T.; Nishizono, S.; Serikawa, T.; Higuchi, K.; Shumiya, S.
Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat
J. Clin. Invest.
116
395-404
2006
Rattus norvegicus (P48450)
brenda
Oliaro-Bosso, S.; Viola, F.; Matsuda, S.; Cravotto, G.; Tagliapietra, S.; Balliano, G.
Umbelliferone aminoalkyl derivatives as inhibitors of oxidosqualene cyclases from Saccharomyces cerevisiae, Trypanosoma cruzi, and Pneumocystis carinii
Lipids
39
1007-1012
2004
Pneumocystis carinii, Saccharomyces cerevisiae, Trypanosoma cruzi
brenda
Thoma, R.; Schulz-Gasch, T.; D'Arcy, B.; Benz, J.; Aebi, J.; Dehmlow, H.; Hennig, M.; Stihle, M.; Ruf, A.
Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase
Nature
432
118-122
2004
Homo sapiens (P48449), Homo sapiens
brenda
Lodeiro, S.; Wilson, W.K.; Shan, H.; Matsuda, S.P.
A putative precursor of isomalabaricane triterpenoids from lanosterol synthase mutants
Org. Lett.
8
439-442
2006
Saccharomyces cerevisiae
brenda
Huff, M.W.; Telford, D.E.
Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear
Trends Pharmacol. Sci.
26
335-340
2005
Homo sapiens, Sus scrofa
brenda
Kolesnikova, M.D.; Xiong, Q.; Lodeiro, S.; Hua, L.; Matsuda, S.P.
Lanosterol biosynthesis in plants
Arch. Biochem. Biophys.
447
87-95
2006
Arabidopsis thaliana
brenda
Galli, U.; Oliaro-Bosso, S.; Taramino, S.; Venegoni, S.; Pastore, E.; Tron, G.C.; Balliano, G.; Viola, F.; Sorba, G.
Design, synthesis, and biological evaluation of new (2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-ol ethers as inhibitors of human and Trypanosoma cruzi oxidosqualene cyclase
Bioorg. Med. Chem. Lett.
17
220-224
2007
Saccharomyces cerevisiae, Homo sapiens, Pneumocystis carinii, Trypanosoma cruzi
brenda
Nakano, C.; Motegi, A.; Sato, T.; Onodera, M.; Hoshino, T.
Sterol biosynthesis by a prokaryote: first in vitro identification of the genes encoding squalene epoxidase and lanosterol synthase from Methylococcus capsulatus
Biosci. Biotechnol. Biochem.
71
2543-2550
2007
Methylococcus capsulatus (Q603D4), Methylococcus capsulatus
brenda
Wu, T.K.; Liu, Y.T.; Chang, C.H.; Yu, M.T.; Wang, H.J.
Site-saturated mutagenesis of histidine 234 of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase demonstrates dual functions in cyclization and rearrangement reactions
J. Am. Chem. Soc.
128
6414-6419
2006
Saccharomyces cerevisiae
brenda
Tanaka, R.; Sakano, Y.; Shimizu, K.; Shibuya, M.; Ebizuka, Y.; Goda, Y.
Constituents of Laurus nobilis L. inhibit recombinant human lanosterol synthase
J. Nat. Med.
60
78-81
2006
Homo sapiens
-
brenda
Lamb, D.C.; Jackson, C.J.; Warrilow, A.G.; Manning, N.J.; Kelly, D.E.; Kelly, S.L.
Lanosterol biosynthesis in the prokaryote Methylococcus capsulatus: insight into the evolution of sterol biosynthesis
Mol. Biol. Evol.
24
1714-1721
2007
Methylococcus capsulatus (Q603D4), Methylococcus capsulatus
brenda
Wu, T.K.; Yu, M.T.; Liu, Y.T.; Chang, C.H.; Wang, H.J.; Diau, E.W.
Tryptophan 232 within oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae influences rearrangement and deprotonation but not cyclization reactions
Org. Lett.
8
1319-1322
2006
Saccharomyces cerevisiae
brenda
Wu, T.K.; Liu, Y.T.; Chiu, F.H.; Chang, C.H.
Phenylalanine 445 within oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae influences C-Ring cyclization and deprotonation reactions
Org. Lett.
8
4691-4694
2006
Saccharomyces cerevisiae
brenda
Suzuki, M.; Xiang, T.; Ohyama, K.; Seki, H.; Saito, K.; Muranaka, T.; Hayashi, H.; Katsube, Y.; Kushiro, T.; Shibuya, M.; Ebizuka, Y.
Lanosterol synthase in dicotyledonous plants
Plant Cell Physiol.
47
565-571
2006
Arabidopsis thaliana (Q1G1A4)
brenda
Sawai, S.; Akashi, T.; Sakurai, N.; Suzuki, H.; Shibata, D.; Ayabe, S.; Aoki, T.
Plant lanosterol synthase: divergence of the sterol and triterpene biosynthetic pathways in eukaryotes
Plant Cell Physiol.
47
673-677
2006
Lotus japonicus
brenda
Teske, B.; Taramino, S.; Bhuiyan, M.S.; Kumaraswami, N.S.; Randall, S.K.; Barbuch, R.; Eckstein, J.; Balliano, G.; Bard, M.
Genetic analyses involving interactions between the ergosterol biosynthetic enzymes, lanosterol synthase (Erg7p) and 3-ketoreductase (Erg27p), in the yeast Saccharomyces cerevisiae
Biochim. Biophys. Acta
1781
359-366
2008
Saccharomyces cerevisiae, Saccharomyces cerevisiae SCY876
brenda
Fouchet, M.H.; Donche, F.; Martin, C.; Bouillot, A.; Junot, C.; Boullay, A.B.; Potvain, F.; Magny, S.D.; Coste, H.; Walker, M.; Issandou, M.; Dodic, N.
Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity
Bioorg. Med. Chem.
16
6218-6232
2008
Homo sapiens
brenda
Wu, T.K.; Chang, C.H.; Liu, Y.T.; Wang, T.T.
Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase: a chemistry-biology interdisciplinary study of the proteins structure-function-reaction mechanism relationships
Chem. Rec.
8
302-325
2008
Saccharomyces cerevisiae
brenda
Dang, H.; Liu, Y.; Pang, W.; Wang, N.; Shyy, J.Y.; Zhu, Y.
Suppression of 2,3-oxidosqualene cyclase by high-fat diet contributes to liver X receptor-alpha -mediated improvement of hepatic lipid profile
J. Biol. Chem.
284
6218-6226
2009
Mus musculus, Rattus norvegicus
brenda
Wu, T.K.; Wen, H.Y.; Chang, C.H.; Liu, Y.T.
Protein plasticity: a single amino acid substitution in the Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase generates protosta-13(17),24-dien-3beta-ol, a rearrangement product
Org. Lett.
10
2529-2532
2008
Saccharomyces cerevisiae
brenda
Wu, T.K.; Wang, T.T.; Chang, C.H.; Liu, Y.T.; Shie, W.S.
Importance of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase tyrosine 707 residue for chair-boat bicyclic ring formation and deprotonation reactions
Org. Lett.
10
4959-4962
2008
Saccharomyces cerevisiae
brenda
Ohyama, K.; Suzuki, M.; Kikuchi, J.; Saito, K.; Muranaka, T.
Dual biosynthetic pathways to phytosterol via cycloartenol and lanosterol in Arabidopsis
Proc. Natl. Acad. Sci. USA
106
725-730
2009
Arabidopsis thaliana
brenda
Seiki, S.; Frishman, W.H.
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia
Cardiol. Rev.
17
70-76
2009
Metazoa
brenda
Taramino, S.; Valachovic, M.; Oliaro-Bosso, S.; Viola, F.; Teske, B.; Bard, M.; Balliano, G.
Interactions of oxidosqualene cyclase (Erg7p) with 3-keto reductase (Erg27p) and other enzymes of sterol biosynthesis in yeast
Biochim. Biophys. Acta
1801
156-162
2010
Saccharomyces cerevisiae, Saccharomyces cerevisiae STY2
brenda
Duniec-Dmuchowski, Z.; Fang, H.L.; Strom, S.C.; Ellis, E.; Runge-Morris, M.; Kocarek, T.A.
Human pregnane X receptor activation and CYP3A4/CYP2B6 induction by 2,3-oxidosqualene:lanosterol cyclase inhibition
Drug Metab. Dispos.
37
900-908
2009
Homo sapiens
brenda
Joffrion, T.M.; Collins, M.S.; Sesterhenn, T.; Cushion, M.T.
Functional characterization and localization of Pneumocystis carinii lanosterol synthase
Eukaryot. Cell
9
107-115
2010
Pneumocystis carinii
brenda
Wu, T.K.; Chang, C.H.; Wen, H.Y.; Liu, Y.T.; Li, W.H.; Wang, T.T.; Shie, W.S.
Alteration of the substrates prefolded conformation and cyclization stereochemistry of oxidosqualene-lanosterol cyclase of Saccharomyces cerevisiae by substitution at phenylalanine 699
Org. Lett.
12
500-503
2010
Saccharomyces cerevisiae, Saccharomyces cerevisiae TKW14
brenda
Taramino, S.; Teske, B.; Oliaro-Bosso, S.; Bard, M.; Balliano, G.
Divergent interactions involving the oxidosqualene cyclase and the steroid-3-ketoreductase in the sterol biosynthetic pathway of mammals and yeasts
Biochim. Biophys. Acta
1801
1232-1237
2010
Homo sapiens, Saccharomyces cerevisiae, Saccharomyces cerevisiae SCY876 and BTY6-5-3
brenda
Kimura, M.; Kushiro, T.; Shibuya, M.; Ebizuka, Y.; Abe, I.
Protostadienol synthase from Aspergillus fumigatus: functional conversion into lanosterol synthase
Biochem. Biophys. Res. Commun.
391
899-902
2010
Aspergillus fumigatus
brenda
Shang, C.H.; Shi, L.; Ren, A.; Qin, L.; Zhao, M.W.
Molecular cloning, characterization, and differential expression of a lanosterol synthase gene from Ganoderma lucidum
Biosci. Biotechnol. Biochem.
74
974-978
2010
Ganoderma lucidum (D7NJ68), Ganoderma lucidum, Ganoderma lucidum HG (D7NJ68)
brenda
Wu, T.K.; Chang, Y.C.; Liu, Y.T.; Chang, C.H.; Wen, H.Y.; Li, W.H.; Shie, W.S.
Mutation of isoleucine 705 of the oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae affects lanosterols C/D-ring cyclization and 17alpha/beta-exocyclic side chain stereochemistry
Org. Biomol. Chem.
9
1092-1097
2011
Saccharomyces cerevisiae
brenda
Chang, C.H.; Chen, Y.C.; Tseng, S.W.; Liu, Y.T.; Wen, H.Y.; Li, W.H.; Huang, C.Y.; Ko, C.Y.; Wang, T.T.; Wu, T.K.
The cysteine 703 to isoleucine or histidine mutation of the oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae generates an iridal-type triterpenoid
Biochimie
94
2376-2381
2012
Saccharomyces cerevisiae
brenda
Hoshino, T.; Chiba, A.; Abe, N.
Lanosterol biosynthesis: the critical role of the methyl-29 group of 2,3-oxidosqualene for the correct folding of this substrate and for the construction of the five-membered D ring
Chemistry
18
13108-13116
2012
Sus scrofa
brenda
Tian, B.X.; Eriksson, L.A.
Catalytic mechanism and product specificity of oxidosqualene-lanosterol cyclase: a QM/MM study
J. Phys. Chem. B
116
13857-13862
2012
Homo sapiens
brenda
Chang, C.H.; Wen, H.Y.; Shie, W.S.; Lu, C.T.; Li, M.E.; Liu, Y.T.; Li, W.H.; Wu, T.K.
Protein engineering of oxidosqualene-lanosterol cyclase into triterpene monocyclase
Org. Biomol. Chem.
11
4214-4219
2013
Saccharomyces cerevisiae
brenda
Liu, Y.T.; Hu, T.C.; Chang, C.H.; Shie, W.S.; Wu, T.K.
Protein engineering of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase into parkeol synthase
Org. Lett.
14
5222-5225
2012
Saccharomyces cerevisiae
brenda
Zhang, D.H.; Li, N.; Yu, X.; Zhao, P.; Li, T.; Xu, J.W.
Overexpression of the homologous lanosterol synthase gene in ganoderic acid biosynthesis in Ganoderma lingzhi
Phytochemistry
134
46-53
2017
Ganoderma lucidum (A0A1L5JY50), Ganoderma lucidum CGMCC 5.616 (A0A1L5JY50)
brenda
Kumar, A.; Fogelman, E.; Weissberg, M.; Tanami, Z.; Veilleux, R.E.; Ginzberg, I.
Lanosterol synthase-like is involved with differential accumulation of steroidal glycoalkaloids in potato
Planta
246
1189-1202
2017
Arabidopsis thaliana (Q1G1A4), Solanum tuberosum (A0A1B0YWV6), Solanum tuberosum
brenda
Kang, L.; Shen, X.; Yang, M.; Zhang, G.; Zhang, J.; Qin, B.; Yang, L.; Hu, N.; Guan, H.
Distribution of lanosterol synthase and lanosterol in cornea, lens and retina tissue of rats
Zhonghua Shiyan Yanke Zazhi
35
201-206
2017
Rattus norvegicus
-
brenda